Tianci International, Inc. (CIIT)

Verve Therapeutics Income Statement

Financials in millions USD. Fiscal year is August - July.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Apr 30, 2025	Jul 31, 2024	Jul 31, 2023	Jul 31, 2022
Operating Revenue	9.13	8.32	-	0.75
Other Revenue	0.33	0.3	0.45	-
Revenue	9.46	8.62	0.45	0.75
Revenue Growth (YoY)	51.52%	1804.75%	-39.91%	-
Cost of Revenue	8.86	7.56	0.46	0.48
Gross Profit	0.6	1.06	-0	0.27
Selling, General & Admin	1.73	0.89	0.34	0.08
Operating Expenses	1.73	0.89	0.34	0.08
Operating Income	-1.12	0.17	-0.34	0.19
Other Non Operating Income (Expenses)	0.03	-0.02	-	-
Pretax Income	-1.09	0.15	-0.34	0.19
Income Tax Expense	0.01	0.04	0.01	0.03
Earnings From Continuing Operations	-1.11	0.11	-0.36	0.16
Minority Interest in Earnings	-0.01	-0.06	0.01	-0.02
Net Income	-1.12	0.05	-0.34	0.14
Net Income to Common	-1.12	0.05	-0.34	0.14
Shares Outstanding (Basic)	15	11	3	2
Shares Outstanding (Diluted)	15	11	3	2
Shares Change (YoY)	78.15%	218.62%	120.98%	-
EPS (Basic)	-0.08	0.01	-0.10	0.10
EPS (Diluted)	-0.08	0.01	-0.10	0.10
Gross Margin	6.38%	12.25%	-0.90%	36.44%
Operating Margin	-11.85%	1.95%	-76.04%	25.48%
Profit Margin	-11.78%	0.63%	-75.42%	19.15%
EBIT	-1.12	0.17	-0.34	0.19
EBIT Margin	-11.85%	1.95%	-76.04%	25.48%
Effective Tax Rate	-	24.55%	-	16.50%
Revenue as Reported	9.46	8.62	0.45	0.75
Advertising Expenses	-	-	0	0

Source: S&P Global Market Intelligence. Standard template. Financial Sources.